Monday, October 25, 2021 5:56:51 PM
Either way i`m only focusing on 1181 now and the cash they have on the books to see it through. Market was overly fixated on Bali in cervical which was small niche as even Management suggested.
Recent AGEN News
- アジーナス、BOT+BALアクセスプログラムの独占的グローバルパートナーにBAP Pharmaを指名 • Business Wire • 04/22/2026 03:56:00 PM
- Agenus désigne BAP Pharma comme partenaire mondial exclusif pour les programmes d’accès à la combinaison BOT+BAL • Business Wire • 04/22/2026 12:55:00 AM
- Agenus ernennt BAP Pharma zum exklusiven globalen Partner für die BOT+BAL-Zugangsprogramme • Business Wire • 04/22/2026 12:55:00 AM
- Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026 • Business Wire • 04/21/2026 02:00:00 PM
- Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs • Business Wire • 04/21/2026 12:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/20/2026 09:21:47 PM
- Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer • Business Wire • 04/17/2026 08:43:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 08:15:10 PM
- Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 • Business Wire • 04/03/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:29 PM
- アジーナス、MSSまたはpMMRの転移性大腸がんを対象としたBOT+BAL免疫療法併用のグローバル第3相BATTMAN試験で初の患者登録を発表 • Business Wire • 04/02/2026 04:31:00 AM
- Agenus annonce le recrutement du premier patient dans l’essai mondial de phase III BATTMAN portant sur l’association immunothérapeutique BOT+BAL dans le cadre du cancer colorectal métastatique MSS ou pMMR • Business Wire • 04/02/2026 04:27:00 AM
- Agenus gibt die Aufnahme des ersten Patienten in die globale Phase-3-Studie BATTMAN bekannt, in der die Immuntherapie-Kombination aus BOT und BAL bei metastasiertem kolorektalem Karzinom der MSS- oder pMMR-Gruppe untersucht wird • Business Wire • 04/02/2026 03:50:00 AM
- Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer • Business Wire • 04/01/2026 11:30:00 AM
- Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access • Business Wire • 03/26/2026 08:52:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 12:24:51 PM
- Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer • Business Wire • 03/17/2026 08:40:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/16/2026 09:19:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 12:15:01 PM
- Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized • Business Wire • 03/16/2026 11:30:00 AM
- Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs • Business Wire • 03/10/2026 11:30:00 AM
- Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update • Business Wire • 03/04/2026 09:30:00 PM
- Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL • Business Wire • 02/19/2026 08:15:00 PM
- Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors • Business Wire • 02/09/2026 06:00:00 PM
- Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 01/23/2026 01:57:55 PM
